Published in J Enzyme Inhib Med Chem on January 09, 2014
Probing the surface of human carbonic anhydrase for clues towards the design of isoform specific inhibitors. Biomed Res Int (2015) 0.83
Anticancer and antiviral sulfonamides. Curr Med Chem (2003) 2.75
Interfering with pH regulation in tumours as a therapeutic strategy. Nat Rev Drug Discov (2011) 2.45
Hypoxia activates the capacity of tumor-associated carbonic anhydrase IX to acidify extracellular pH. FEBS Lett (2004) 2.33
Carbonic anhydrase inhibitors: inhibition of the transmembrane isozyme XIV with sulfonamides. Bioorg Med Chem Lett (2005) 2.24
Synthesis and antimalarial activity of novel chiral and achiral benzenesulfonamides bearing 1, 3, 4-oxadiazole moieties. J Enzyme Inhib Med Chem (2007) 2.00
CHO1, a mammalian kinesin-like protein, interacts with F-actin and is involved in the terminal phase of cytokinesis. J Cell Biol (2002) 1.79
Recent developments in targeting carbonic anhydrase IX for cancer therapeutics. Oncotarget (2012) 1.77
Targeting tumor hypoxia: suppression of breast tumor growth and metastasis by novel carbonic anhydrase IX inhibitors. Cancer Res (2011) 1.76
Oxovanadium(IV) complexes of hydrazides: potential antifungal agents. J Enzyme Inhib Med Chem (2006) 1.73
Carbonic anhydrases: current state of the art, therapeutic applications and future prospects. J Enzyme Inhib Med Chem (2004) 1.72
Carbonic anhydrase in the scleractinian coral Stylophora pistillata: characterization, localization, and role in biomineralization. J Biol Chem (2008) 1.70
Unexpected nanomolar inhibition of carbonic anhydrase by COX-2-selective celecoxib: new pharmacological opportunities due to related binding site recognition. J Med Chem (2004) 1.57
The role of carbonic anhydrase 9 in regulating extracellular and intracellular ph in three-dimensional tumor cell growths. J Biol Chem (2009) 1.53
Isatin-derived antibacterial and antifungal compounds and their transition metal complexes. J Enzyme Inhib Med Chem (2004) 1.52
HIV-1 protease inhibitors from inverse design in the substrate envelope exhibit subnanomolar binding to drug-resistant variants. J Am Chem Soc (2008) 1.43
Multiple binding modes of inhibitors to carbonic anhydrases: how to design specific drugs targeting 15 different isoforms? Chem Rev (2012) 1.43
Crystal structure of the catalytic domain of the tumor-associated human carbonic anhydrase IX. Proc Natl Acad Sci U S A (2009) 1.43
Highly active antiretroviral therapy: current state of the art, new agents and their pharmacological interactions useful for improving therapeutic outcome. Curr Pharm Des (2005) 1.43
Carbonic anhydrase inhibitors: E7070, a sulfonamide anticancer agent, potently inhibits cytosolic isozymes I and II, and transmembrane, tumor-associated isozyme IX. Bioorg Med Chem Lett (2004) 1.42
Design, synthesis, and evaluation of hydroxamic acid derivatives as promising agents for the management of Chagas disease. J Med Chem (2013) 1.42
Biochemical characterization of CA IX, one of the most active carbonic anhydrase isozymes. J Biol Chem (2008) 1.42
Tumor-associated carbonic anhydrase 9 spatially coordinates intracellular pH in three-dimensional multicellular growths. J Biol Chem (2008) 1.40
A quantitative model of thermal stabilization and destabilization of proteins by ligands. Biophys J (2008) 1.40
Evaluating the substrate-envelope hypothesis: structural analysis of novel HIV-1 protease inhibitors designed to be robust against drug resistance. J Virol (2010) 1.39
Carbonic anhydrase IX from cancer-associated fibroblasts drives epithelial-mesenchymal transition in prostate carcinoma cells. Cell Cycle (2013) 1.34
Carbonic anhydrase inhibitors: inhibition of the tumor-associated isozyme IX with aromatic and heterocyclic sulfonamides. Bioorg Med Chem Lett (2003) 1.32
Inhibitors of HIV-1 protease: current state of the art 10 years after their introduction. From antiretroviral drugs to antifungal, antibacterial and antitumor agents based on aspartic protease inhibitors. Curr Med Chem (2007) 1.30
Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associated) and XIV with 4-substituted 3-pyridinesulfonamides. Eur J Med Chem (2010) 1.30
Solution structure and functional ligand screening of HI0719, a highly conserved protein from bacteria to humans in the YjgF/YER057c/UK114 family. Biochemistry (2003) 1.30
Anticonvulsant sulfonamides/sulfamates/sulfamides with carbonic anhydrase inhibitory activity: drug design and mechanism of action. Curr Pharm Des (2008) 1.29
Targeting tumor-associated carbonic anhydrase IX in cancer therapy. Trends Pharmacol Sci (2006) 1.27
TP53 codon 72 polymorphism and cervical cancer: a pooled analysis of individual data from 49 studies. Lancet Oncol (2009) 1.26
Novel organometallic cationic ruthenium(II) pentamethylcyclopentadienyl benzenesulfonamide complexes targeted to inhibit carbonic anhydrase. J Biol Inorg Chem (2009) 1.26
Carbonic anhydrase inhibitors. Novel sulfanilamide/acetazolamide derivatives obtained by the tail approach and their interaction with the cytosolic isozymes I and II, and the tumor-associated isozyme IX. Bioorg Med Chem Lett (2005) 1.26
Carbonic anhydrase inhibitors: novel sulfonamides incorporating 1,3,5-triazine moieties as inhibitors of the cytosolic and tumour-associated carbonic anhydrase isozymes I, II and IX. Bioorg Med Chem Lett (2005) 1.25
2-substituted estradiol bis-sulfamates, multitargeted antitumor agents: synthesis, in vitro SAR, protein crystallography, and in vivo activity. J Med Chem (2006) 1.25
Metal-Based Antibacterial and Antifungal Agents: Synthesis, Characterization, and In Vitro Biological Evaluation of Co(II), Cu(II), Ni(II), and Zn(II) Complexes With Amino Acid-Derived Compounds. Bioinorg Chem Appl (2006) 1.21
Characterization of CA XIII, a novel member of the carbonic anhydrase isozyme family. J Biol Chem (2003) 1.19
ESI mass spectrometry and X-ray diffraction studies of adducts between anticancer platinum drugs and hen egg white lysozyme. Chem Commun (Camb) (2006) 1.19
A new coral carbonic anhydrase in Stylophora pistillata. Mar Biotechnol (NY) (2011) 1.18
Epithelial carbonic anhydrases facilitate PCO2 and pH regulation in rat duodenal mucosa. J Physiol (2006) 1.17
Evaluation of the substrate envelope hypothesis for inhibitors of HIV-1 protease. Proteins (2007) 1.17
Direct extracellular interaction between carbonic anhydrase IV and the human NBC1 sodium/bicarbonate co-transporter. Biochemistry (2003) 1.17
Sulfonamide linked neoglycoconjugates--a new class of inhibitors for cancer-associated carbonic anhydrases. J Med Chem (2010) 1.16
Influenza virus ribonucleoprotein complexes gain preferential access to cellular export machinery through chromatin targeting. PLoS Pathog (2011) 1.16
Specific inhibition of carbonic anhydrase IX activity enhances the in vivo therapeutic effect of tumor irradiation. Radiother Oncol (2011) 1.15
Ureido-substituted benzenesulfonamides potently inhibit carbonic anhydrase IX and show antimetastatic activity in a model of breast cancer metastasis. J Med Chem (2011) 1.13
Non-zinc mediated inhibition of carbonic anhydrases: coumarins are a new class of suicide inhibitors. J Am Chem Soc (2009) 1.13
Root effect hemoglobin may have evolved to enhance general tissue oxygen delivery. Science (2013) 1.13
Sulfamates and their therapeutic potential. Med Res Rev (2005) 1.12
Design of mutation-resistant HIV protease inhibitors with the substrate envelope hypothesis. Chem Biol Drug Des (2007) 1.12
In vitro antibacterial, antifungal & cytotoxic activity of some isonicotinoylhydrazide Schiff's bases and their cobalt (II), copper (II), nickel (II) and zinc (II) complexes. J Enzyme Inhib Med Chem (2006) 1.11
Zinc complexes of benzothiazole-derived Schiff bases with antibacterial activity. J Enzyme Inhib Med Chem (2003) 1.10
New strategies for targeting the hypoxic tumour microenvironment in breast cancer. Cancer Treat Rev (2012) 1.08
Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem (2010) 1.06
Phosphorylation of carbonic anhydrase IX controls its ability to mediate extracellular acidification in hypoxic tumors. Cancer Res (2011) 1.05
Targeting hypoxic tumor cell viability with carbohydrate-based carbonic anhydrase IX and XII inhibitors. J Med Chem (2011) 1.05
Therapeutic potential of sulfamides as enzyme inhibitors. Med Res Rev (2006) 1.05
Carbonic anhydrase inhibitors. Inhibition of human tumor-associated isozymes IX and cytosolic isozymes I and II with some 1,3,4-oxadiazole-thiols. J Enzyme Inhib Med Chem (2006) 1.05
The development of topically acting carbonic anhydrase inhibitors as antiglaucoma agents. Curr Pharm Des (2008) 1.04
Taking advantage of tumor cell adaptations to hypoxia for developing new tumor markers and treatment strategies. J Enzyme Inhib Med Chem (2009) 1.04
Rational drug repositioning guided by an integrated pharmacological network of protein, disease and drug. BMC Syst Biol (2012) 1.03
Synthesis of coumarin derivatives with cytotoxic, antibacterial and antifungal activity. J Enzyme Inhib Med Chem (2004) 1.03
Carbonic anhydrase inhibitors: anticonvulsant sulfonamides incorporating valproyl and other lipophilic moieties. J Med Chem (2002) 1.02
Imaging of CA IX with fluorescent labelled sulfonamides distinguishes hypoxic and (re)-oxygenated cells in a xenograft tumour model. Radiother Oncol (2009) 1.02
CO2 permeability of cell membranes is regulated by membrane cholesterol and protein gas channels. FASEB J (2012) 1.02
Carbonic anhydrase inhibitors. Inhibition of the transmembrane isozyme XII with sulfonamides-a new target for the design of antitumor and antiglaucoma drugs? Bioorg Med Chem Lett (2005) 1.01
Selective inhibition of carbonic anhydrase IX decreases cell proliferation and induces ceramide-mediated apoptosis in human cancer cells. J Pharmacol Exp Ther (2010) 1.01
Carbonic anhydrase IX: Biochemical and crystallographic characterization of a novel antitumor target. Biochim Biophys Acta (2009) 1.00
Synthesis, characterization and biological studies of sulfonamide Schiff's bases and some of their metal derivatives. J Enzyme Inhib Med Chem (2011) 1.00
Imaging the hypoxia surrogate marker CA IX requires expression and catalytic activity for binding fluorescent sulfonamide inhibitors. Radiother Oncol (2007) 1.00
The functional and physical relationship between the DRA bicarbonate transporter and carbonic anhydrase II. Am J Physiol Cell Physiol (2002) 0.99
Designing of novel carbonic anhydrase inhibitors and activators. Curr Med Chem Cardiovasc Hematol Agents (2004) 0.98
Membrane-bound carbonic anhydrases in osteoclasts. Bone (2006) 0.98
An update in the development of HIV entry inhibitors. Curr Top Med Chem (2007) 0.98
Carbonic anhydrase inhibitors: clash with Ala65 as a means for designing inhibitors with low affinity for the ubiquitous isozyme II, exemplified by the crystal structure of the topiramate sulfamide analogue. J Med Chem (2006) 0.97
Inhibition of carbonic anhydrase isozymes I, II and IX with benzenesulfonamides containing an organometallic moiety. Bioorg Med Chem Lett (2007) 0.97
Cloning, characterization, and inhibition studies of a beta-carbonic anhydrase from Brucella suis. J Med Chem (2010) 0.97
Carbonic anhydrases in anthozoan corals-A review. Bioorg Med Chem (2012) 0.97
Therapeutic applications of glycosidic carbonic anhydrase inhibitors. Med Res Rev (2009) 0.96
In-vitro antibacterial, antifungal and cytotoxic activities of some coumarins and their metal complexes. J Enzyme Inhib Med Chem (2005) 0.96
Carbonic anhydrase inhibitors. Cloning, characterization, and inhibition studies of a new beta-carbonic anhydrase from Mycobacterium tuberculosis. J Med Chem (2009) 0.96
Carbonic anhydrase inhibitors. Inhibition of the prokariotic beta and gamma-class enzymes from Archaea with sulfonamides. Bioorg Med Chem Lett (2004) 0.96
Carbonic anhydrase inhibitors: inhibition of human cytosolic isozyme II and mitochondrial isozyme V with a series of benzene sulfonamide derivatives. Bioorg Med Chem Lett (2004) 0.96
Targeting tumour hypoxia to prevent cancer metastasis. From biology, biosensing and technology to drug development: the METOXIA consortium. J Enzyme Inhib Med Chem (2014) 0.96
Non-peptidic chemokine receptors antagonists as emerging anti-HIV agents. J Enzyme Inhib Med Chem (2002) 0.95
Adverse cardiovascular effects of the coxibs. J Med Chem (2005) 0.95
Carbonic anhydrase inhibitors. Design of selective, membrane-impermeant inhibitors targeting the human tumor-associated isozyme IX. J Med Chem (2004) 0.95